title: The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.
abstract: Women with germline mutations in BRCA1 and BRCA2 genes have significantly increased lifetime risks of breast and ovarian cancer. To manage both the ovarian and breast cancer risks the current recommendation is undergo a risk reducing salpingo-oophorectomy (RRSO) prior to natural menopause. To date, studies have focussed on quality of life and sexual dysfunction in women who undergo RRSO, but few have reported on the wider physical consequences. We performed a questionnaire study in women with BRCA 1 or 2 gene mutations known to the Peter MacCallum Familial Cancer Centre. We gathered information about ovarian surgery, ongoing follow-up, management of risk factors including osteoporosis, and current severity of menopausal symptoms. Two hundred and nineteen women were surveyed. One hundred and forty-three of 157 responding participants (91 %) reported having RRSO. Sixty one were pre-menopausal at RRSO. Post surgical follow-up rates were generally low, and a minority of women reported recent bone density imaging or pharmaceutical prevention or treatment of osteoporosis. Menopausal symptoms appeared generally mild. No significant differences in symptom severity were observed in women who underwent a pre-menopausal RRSO compared to RRSO after natural menopause. These data indicate that a formalised follow-up protocol is necessary to optimally manage the consequences of a RRSO.
authors.affiliation: Familial Cancer Centre, Peter MacCallum Cancer Centre, Level 3, 10 St Andrews Place, East Melbourne, VIC, 3002, Australia.
authors.forename: Carmel
authors.initials: C
authors.lastname: Pezaro
authors.forename: Paul
authors.initials: P
authors.lastname: James
authors.forename: Joanne
authors.initials: J
authors.lastname: McKinley
authors.forename: Mary
authors.initials: M
authors.lastname: Shanahan
authors.forename: Mary-Anne
authors.initials: MA
authors.lastname: Young
authors.forename: Gillian
authors.initials: G
authors.lastname: Mitchell
mesh_terms: D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009154:Mutation; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010052:Ovariectomy / Q000379:methods*; D017697:Premenopause; D040242:Risk Reduction Behavior; D012489:Salpingostomy / Q000379:methods; D011795:Surveys and Questionnaires
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human